DEMENTIA IN SWEDISH TWINS

描述：(改编自申请人摘要)。此应用程序寻求 继续支持瑞典双胞胎痴呆症研究以扩大 通过对所有阿尔茨海默病病例的全面确证进行抽样 和其他晚年痴呆症患者在整个瑞典双胞胎登记处。这个 估计要完成200多对数据，其中一对或两对都是 被诊断为阿尔茨海默氏症的350对夫妇中，其中一人或双方都有 任何痴呆症的诊断。病例识别将使用电话筛查 样本中的所有个人，然后是线人面谈 那些证据受损的人，导致认知筛查数据来自 超过6000对完整的配对。与医疗保健利用的记录联系将是 作为一项平行的案件鉴定战略开展。诊断性 对筛查结果呈阳性的患者的评估将包括体检 评估、神经心理测量、神经成像和告密者 采访。合作伙伴将收到相同的协议， 筛查阴性的个体的独立样本。风险和 保护因素将从举报人面谈中获得，体检 记录和孪生登记数据库，职业历史链接到 可测量的曝光量。包括一次纵向跟踪，并允许 将被要求进行尸检。利用数量遗传学进行数据分析 方法将解决六个问题：1)相对重要性是什么 阿尔茨海默病的遗传和环境影响？2)什么是 衡量潜在遗传风险和量化风险的最佳指数 可变性？3)可以识别哪些非遗传风险因素？4)什么 影响发病年龄？5)遗传因素与发病年龄之间是否存在交互作用 环境风险因素？和6)赔偿责任的共同变动是什么 不同类型的障碍？分析技术将包括扩展 责任门槛模型到混合模型、性别限制模型、使用 使用配对的测量基因、双变量模型和病例对照方法 双胞胎设计。将对不同的诊断标准进行比较。量化 指数将从神经心理评分和神经成像中得出 进行定量测绘的数据。

DESCRIPTION: (Adapted from Applicant's Abstract). This application seeks continued support for the Study of Dementia in Swedish Twins to expand the sample by means of total ascertainment of all cases of Alzheimer's disease and other late-life dementias in the entire Swedish Twin Registry. The estimate is to complete data for over 200 pairs in which one or both is diagnosed with Alzheimer's disease, and 350 pairs in which one or both has any dementia diagnosis. Case identification will use telephone screening with all individuals in the sample, followed by informant interviews for those with evidence impairment, resulting in cognitive screening data from over 6000 complete pairs. Record linkage to health care utilization will be carried out as a parallel case identification strategy. Diagnostic assessment for those with a positive screening outcome will include medical evaluation, neuropsychological measures, neuroimaging, and informant interviews. Partners will receive the identical protocol, as will an independent sample of individuals who screened negative. Risk and protective factors will be obtained from the informant interview, medical records, and twin registry database, with occupational history linked to measured exposures. One longitudinal follow-up is included, and permission for autopsy will be requested. Data analyses using quantitative genetic approaches will address six questions: 1) What is the relative importance of genetic and environmental effects of Alzheimer's disease? 2) What are the best indices of the underlying genetic liability and of quantitative variability? 3) What non-genetic risk factors can be identified? 4) What influences age of onset? 5) Are there interactions between genetic and environmental risk factors? and 6) What is the covariation of liability to different types of disorder? Analytic techniques will include expansion of liability threshold models to mixed models, sex limitation models, use of measured genotype, bivariate models, and case-control methods using matched twin designs. Different diagnostic criteria will be compared. Quantitative indices will be derived from neuropsychological scores and from neuroimaging data subjected to quantitative mapping.